Galena Biopharma Earnings Report: "P.S. -- We're Under Investigation"

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

It pays to read the fine print.

Galena Biopharma (NASDAQ: GALE  ) reported its fourth-quarter results after the market closed on Monday. There were plenty of financial numbers to digest, of course, and a few interesting updates on the company's products and leadership team. The biggest news, though, didn't make the earnings announcement press release at all and wasn't mentioned until the bottom of page 37 of Galena's 10-K filing to the SEC. 

What was that big news? Galena revealed that it learned in February that the SEC is investigating "certain matters related to our company and an outside investor-relations firm that we retained in 2013." The biotech stated that it has been in contact with the SEC and is cooperating with the investigation. Galena's shares dropped more than 9% in after-hours trading on Monday.

Source: Galena Biopharma.

Postscript from posts
The two sentences in the 10-K seem sort of like a postscript in a letter: "P.S. --By the way, we're under investigation." The federal investigation postscript appears to be related to several online posts made earlier this year.

On Feb. 12, The Street's Adam Feuerstein reported that The DreamTeam Group, a stock-promotions firm, published multiple online articles touting Galena under pseudonyms that made the articles appear to have been written by individual investors. He also noted that insiders with the biotech made millions of dollars in January by selling shares after the stock tripled in value with assistance from the promotions. Galena's stock nosedived on the revelations.

Galena responded a couple of days later in a letter to its shareholders. CEO Mark Ahn stated that Feuerstein "clearly has an agenda when it comes to Galena." Ahn acknowledged that the biotech had previously engaged The DreamTeam Group and that insiders had sold shares in January. However, he said Feuerstein's accusations were "specious and conveniently arranged to create controversy." 

This story continued last week when an investor, Richard Pearson, wrote in an article published on the website Seeking Alpha that The DreamTeam Group offered to pay him to promote Galena and CytRx Corporation (NASDAQ: CYTR  ) . Seeking Alpha pulled several articles from its website following Pearson's allegations. Several other online financial websites, including The Motley Fool, have also removed articles related to this controversy. 

Signal or noise?
In that letter to shareholders, Ahn dismissed negative articles as "noise" to his company. The question for investors is whether he's right or if the SEC investigation is really more signal than noise.

Galena doesn't appear to be taking the SEC investigation lightly. The company announced the addition of Irving Einhorn to its board of directors. Einhorn is a former regional administrator with the SEC and has served as an attorney specializing in securities enforcement and compliance.

That said, there is at least a partial reason this biotech stock racked up big gains in the fourth quarter of last year. Galena could have a winner with NeuVax, a cancer immunotherapy that is in phase 3 clinical studies.Teva Pharmaceuticals (NYSE: TEVA  ) acquired the rights to market NeuVax in Israel last December. The financial details of the deal weren't announced, but Teva will pay royalties to Galena if the drug gains approval.

More recently, Dr. Reddy's Laboratories (NYSE: RDY  ) gained the rights to market NeuVax in India. As with the Teva deal, few financial details were announced regarding the Dr. Reddy's agreement. However, Galena stated that it would "receive development and sales milestones, as well as double-digit royalties on net sales."

Teva and Dr. Reddy's weren't interested in NeuVax for nothing. Earlier clinical results showed promise. At least one analyst, Zacks' Grant Zeng, thinks the drug could easily become a blockbuster if it secures regulatory approval.

I suspect they're all correct in their outlooks. If NeuVax lives up to its potential, the slamming of shares resulting from the SEC investigation could prove to be overdone. However, my investing style tends to be somewhat cautious, so I'll hold off on taking action with Galena. And I'll make sure to read the fine print.

P.S. -- this stock could be one for you to investigate.
Looking for a great investing idea? The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Read/Post Comments (2) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 20, 2014, at 7:29 PM, dontworrycmurray wrote:

    Well written balanced article. I only wish the other authors of certain blogging sites would follow you balanced approach. But then again most have an agenda that sometimes they disclose and sometimes not.

  • Report this Comment On March 20, 2014, at 11:18 PM, indy1643 wrote:

    It appeared to me that Rck Pearson's article was quite incriminating until I came across another piece written by him on January 27,2014 touting Galena. He highlighted the promising research, numerous trials recent acquisition, partnership with Dr Reddy in India, agreement with Teva over Neuvax in Israel,Abstral potential, coverage by Oppenheimer, etc. The primary reasons the share price rose.

    How can he publish a story six weeks later implying that he went deeply undercover, did extensive research and came to the conclusion that the company was up to no good. The timeline simply makes no sense.

    I hope the SEC does an extremely thorough investigation of all the parties involved. Are there any law firms left in the country that haven't climbed aboard the Galena train ? I hope the judgement is impartial and swift.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2881805, ~/Articles/ArticleHandler.aspx, 9/1/2015 4:30:20 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Keith Speights

Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Today's Market

updated Moments ago Sponsored by:
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASD 4,636.11 -140.40 -2.94%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 4:00 PM
GALE $1.58 Down +0.00 +0.00%
Galena Biopharma,… CAPS Rating: *
RDY $63.70 Down -1.37 -2.11%
Dr. Reddy's Labora… CAPS Rating: ****
TEVA $63.18 Down -1.23 -1.91%
Teva Pharmaceutica… CAPS Rating: *****